Modulator assay
AssigneeUcb Biopharma Srl
InventorsJames Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, Graham John WARRELLOW
Life of this patent
Estimating the term…
Abstract
It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.
Claims22
A method for identifying a compound that is capable of binding to a trimeric protein that is a tumor necrosis factor (TNF) superfamily member, whereby the compound-trimer complex binds to the requisite TNF superfamily receptor and modulates the signalling of the receptor, comprising:
- a) identifying the binding of the compound to the trimeric form of the TNF superfamily member in a sample;
- and/or
- b) measuring the stability of the trimeric form of the TNF superfamily member in a sample comprising the compound;
- and/or
- c) measuring the level of trimeric TNF superfamily member bound to the requisite receptor in a sample comprising the compound;
- and/or
- d) measuring the competition of the compound with a probe compound for binding to the trimeric form of the TNF superfamily member;
- and comparing the binding of the compound to the trimeric form of the TNF superfamily member in (a), and/or the stability of the trimeric form of the TNF superfamily member in (b), and/or the level of trimeric TNF superfamily member bound to the requisite receptor in (c), and/or the level of competition observed in (d) to corresponding values from control samples and selecting a compound that is capable of binding to a trimeric protein that is a TNF superfamily member, whereby the compound-trimer complex binds to the requisite TNF superfamily receptor and modulates the signalling of the receptor.
13-14. (canceled)
23-40. (canceled)
Dependencies are inferred from the claim text.